Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Amitriptyline hydrochloride + choline** is an oral combination product marketed as **Sentra PM** or **SentraVil PM**, described as a convenience-packed medical food and drug kit distributed by Targeted Medical Pharma through Physician Therapeutics. The pharmaceutical component is **amitriptyline hydrochloride**, a small-molecule tricyclic antidepressant that inhibits presynaptic reuptake of **serotonin** and **norepinephrine**, while the accompanying choline component is supplied as **choline bitartrate** within a proprietary nutritional formulation that may also include amino acids and related ingredients. The product appears to have been positioned primarily around depression-related use, although amitriptyline itself is also used more broadly for disorders such as major depressive disorder, neuropathic pain, and migraine prevention. Based on the provided context, this is best understood as a combination product that includes an established antidepressant together with a choline-containing medical food formulation rather than a novel molecular entity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on amitriptyline hydrochloride + choline.